Kiniksa Pharmaceuticals announced the termination of its license agreement with MedImmune for mavrilimumab effective May 22, 2025, and reported financial results for the year ending December 31, 2024, along with a plan to discontinue a clinical trial for abiprubart, incurring approximately $19 million in expenses and expecting an additional $14 million to $17 million in costs.